Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/ijms18061331 http://scihub22266oqcxt.onion/10.3390/ijms18061331 C5486151!5486151!28635644     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Mol+Sci 2017 ; 18 (6): ä Nephropedia Template TP {{tp|p=28635644|t=2017. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression |pdf=|usr=}}{{28635644}} gab.com Text PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression JO: Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=28635644 #FOAvip The therapy of different advanced-stage malignancies with monoclonal antibodies blocking programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) signaling has had an impressive long-lasting effect in a portion of patients, but in most cases, this therapy was not successful, or a secondary resistance developed. To enhance its efficacy in treated patients, predictive biomarkers are searched for and various combination treatments are intensively investigated. As the downregulation of major histocompatibility complex (MHC) class I molecules is one of the most frequent mechanisms of tumor escape from the host?s immunity, it should be considered in PD-1/PD-L1 checkpoint inhibition. The potential for the use of a PD-1/PD-L1 blockade in the treatment of tumors with aberrant MHC class I expression is discussed, and some strategies of combination therapy are suggested. Twit Text FOAVip PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression ????Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=28635644 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28635644 #FOAvip English Wikipedia <ref>{{Cite pmid|28635644}}</ref> PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression #MMPMID28635644 ?mahel M Int J Mol Sci 2017[Jun]; 18 (6): ä PMID28635644show ga The therapy of different advanced-stage malignancies with monoclonal antibodies blocking programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) signaling has had an impressive long-lasting effect in a portion of patients, but in most cases, this therapy was not successful, or a secondary resistance developed. To enhance its efficacy in treated patients, predictive biomarkers are searched for and various combination treatments are intensively investigated. As the downregulation of major histocompatibility complex (MHC) class I molecules is one of the most frequent mechanisms of tumor escape from the host?s immunity, it should be considered in PD-1/PD-L1 checkpoint inhibition. The potential for the use of a PD-1/PD-L1 blockade in the treatment of tumors with aberrant MHC class I expression is discussed, and some strategies of combination therapy are suggested. äPD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I (epmc).pdf DeepDyve Pubget Overpricing